Skip to Content

Palonosetron Dosage

Medically reviewed by Drugs.com. Last updated on Jan 4, 2021.

Applies to the following strengths: 0.25 mg/2 mL; 0.25 mg/5 mL; 0.075 mg/1.5 mL

Usual Adult Dose for Nausea/Vomiting - Chemotherapy Induced

0.25 mg via IV infusion over 30 seconds ONCE 30 minutes before the start of chemotherapy

Comments:
-The infusion line should be flushed with normal saline prior to and after administration of this drug.
-This drug should not be mixed with other drugs.

Uses:
-Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy
-Prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy

Usual Adult Dose for Nausea/Vomiting - Postoperative

0.075 mg via IV injection over 10 seconds ONCE immediately before induction of anesthesia

Comments:
-Efficacy beyond 24 hours has not been determined.
-Routine prophylaxis is not recommended in patients in whom there is little expectation of postoperative nausea/vomiting (PONV).
-Use is recommended in situations where nausea/vomiting must be avoided in the postoperative period, even when the incidence of PONV is low.

Use: Prevention of PONV for up to 24 hours following surgery

Usual Pediatric Dose for Nausea/Vomiting - Chemotherapy Induced

1 month to younger than 17 years: 20 mcg/kg via IV infusion over 15 seconds ONCE 30 minutes before the start of chemotherapy
-Maximum dose: 1.5 mg

17 years and older: 0.25 mg via IV infusion over 30 seconds ONCE 30 minutes before the start of chemotherapy

Comments:
-The infusion line should be flushed with normal saline prior to and after administration of this drug.
-This drug should not be mixed with other drugs.

Uses:
-Patients 1 month to younger than 17 years: Prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy
-Patients 17 years and older: Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy
-Patients 17 years and older: Prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Experience with repeat dosing within a course of multi-day chemotherapy is limited.

This drug may increase large bowel transit time; therefore, it is recommended to monitor patients with a history of constipation or signs of subacute intestinal obstruction following administration.

Precautions

CONTRAINDICATIONS:
-Hypersensitivity to the active component or any of the ingredients

Safety and effectiveness have not been established in patients younger than 1 month.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-This drug may be taken without regard to meals.
-This drug should be infused intravenously over 30 seconds.
-The IV infusion line should be flushed with normal saline before and after administration of this drug.

Storage requirements:
-This drug should be stored between 20 to 25 C and protected from light.

Patient advice:
-This drug may cause drowsiness, fatigue, or somnolence; patients should be advised to avoid driving or operating machinery if they feel drowsy or dizzy.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.